# Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure

> **NCT06651970** · PHASE4 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 60 (estimated)

## Conditions studied

- Chronic Lymphocytic Leukaemia
- Heart Failure

## Interventions

- **DRUG:** Acalabrutinib
- **OTHER:** Investigator's choice of treatment

## Key facts

- **NCT ID:** NCT06651970
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-04
- **Primary completion:** 2030-08-16
- **Final completion:** 2030-08-16
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-05-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06651970

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06651970, "Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure". Retrieved via AI Analytics 2026-07-24 from https://api.ai-analytics.org/clinical/NCT06651970. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*